Cisplatin as an active treatment in zoledronate-refractory hypercalcemia

Annals of Oncology

Volumn 22, Issue 5, 2011, Pages 1244-1246

  Lin, P H ^a,b   Chiu, C F ^b   Lu, Y S ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CA 15-3 ANTIGEN; CALCITONIN; CISPLATIN; ESTROGEN RECEPTOR; EXEMESTANE; FLUOROURACIL; FOLINIC ACID; NAVELBINE; PROGESTERONE RECEPTOR; ZOLEDRONIC ACID;

ADULT; BONE METASTASIS; BREAST CARCINOMA; CANCER RECURRENCE; CASE REPORT; DRUG DOSE INCREASE; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HUMAN; HYPERCALCEMIA; LETTER; MASTECTOMY; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; TREATMENT FAILURE;

EID: 79955499719     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr123     Document Type: Letter

References (5)

1. Stewart AF. Hypercalcemia associated with cancer. N Engl J Med 2005; 352: 373-379.
2. Yeh KH, Lu YS, Hsu CH et al. Phase II study of weekly vinorelbine and 24-h infusion of high-dose 5-fluorouracil plus leucovorin as first-line treatment of advanced breast cancer. Br J Cancer 2005; 92: 1013-1018.
3. Wenzel C, Bartsch R, Hussian D et al. Zoledronate in a patient with pamidronate refractory hypercalcemia syndrome. Support Care Cancer 2004; 12: 678-681.
4. Kukla LJ, Abramson EC, McGuire WP et al. Cis-platinum treatment for malignancy-associated humoral hypercalcemia in an athymic mouse model. Calcif Tissue Int 1984; 36: 559-562.
5. Lad TE, Mishoulam HM, Shevrin DH et al. Treatment of cancer-associated hypercalcemia with cisplatin. Arch Intern Med 1987; 147: 329-332.